Revenue Conversations

A pressing issue arises as expenses remain off the table for discussion, pushing the focus toward revenue and taxation instead. Potential changes in Medicare reimbursement policies for drugs like Wagovi and Ozempic may introduce significant shifts, though their implications are still uncertain. Exploring these alternatives could lead to profound impacts on government funding and healthcare.